29 results on '"Chantima, Warangkana"'
Search Results
2. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
3. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
4. Immunogenicity and durability against micron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
5. Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection.
6. Neutralizing antibodies against omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity
7. Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy
8. Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer
9. Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
10. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
11. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
12. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
13. Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
14. Safety and Immunogenicity of Intradermal Administration of Fractional Dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as Primary Series Vaccination
15. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
16. Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination
17. Improved sensitivity of influenza A antigen detection using a combined NP, M, and NS1 sandwich ELISA
18. Omicron BA.1, BA.2 and COVID-19 Booster Vaccination
19. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
20. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
21. Rapid and sensitive lateral flow immunoassay for influenza antigen using fluorescently-doped silica nanoparticles
22. EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
23. Production, characterization, and in vitro effects of a novel monoclonal antibody against Mig-7
24. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application
25. Rapid and sensitive lateral flow immunoassay for influenza antigen using fluorescently-doped silica nanoparticles
26. Combined gold nanoparticle-antibody conjugate enhances sensitivity of influenza a antigen detection in lateral flow assay
27. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination.
28. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.
29. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac ® , ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.